Arthritis & Rheumatism, Volume 60,
October 2009 Abstract Supplement

The 2009 ACR/ARHP Annual Scientific Meeting
Philadelphia October 16-21, 2009.


Antibody against Mutated Citrullinated Vimentin (anti-MCV) as a Serological Marker for Juvenile Idiopathic Arthritis

Lora1,  Priscila, Machado2,  Sandra, Xavier3,  Ricardo M.

Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil
Porto Alegre, Brazil

Background:

RF, ANA and anti-CCP are some biomarkers that have been used in the diagnostic of JIA. Nevertheless none of them have demonstrated great predictive value for this use. It has been suggested that anti-MCV antibodies are more sensitive than anti-CCP antibodies to diagnose RA and also that it correlates with RA activity (DAS 28).

Purpose:

To study the presence of anti-MCV antibodies in a group of patients with AIJ.

Methods:

Anti-MCV antibodies were tested in serum from 33 patients with JIA and 7 control individuals without symptoms or signs of rheumatic diseases using an ELISA test (Orgentec, Grm). Anti-CCP antibodies were tested by ELISA test, second generation (DIASTAT, Scotland). The procedures were conducted according to the manufacturer's instructions. All measurements were performed by experienced operators who were blinded to clinical conditions. The study was approved by local ethics committee.

Results:

Anti-MCV was observed in 30.3% of JIA patients (10/33), being absent in all controls (specificity= 100%). Besides, none of JIA patients presented anti-CCP antibodies. In clinical aspects, there was no difference in the age of onset (p = 0.12) and duration of the disease (p = 0.37) between those who were anti-MCV positive or negative. Polyarthritis was the most frequent subtype (39% 13/33) and showed the highest prevalence of anti-MCV (15.5%, 5/33). (table I).

Table I. JIA patients' demographic data and biomarkers frequency.

JIA subtypePolyarthrits (n=13)Oligoarthritis (n =12)Systemic (n = 5)Psoriatics (n = 3)
Demographic data    
Age (in years, mean (SD))9.1 (3.0)12.6 (5.1)8.7 (3.3)11.9 (6.3)
Age of onset (in years, mean (SD))4.5 (2.9)6.0 (3.2)5.5 (4.4)4.7 (1.1)
during of the disease (in years, median (amplitude))3.5 (2.4–7)7.6 (2.6–9.6)3.2 (1.5)6.3 (1.3–9.6)
Biomarkers    
Anti-MCV (% (n))38.5 (5)8.3 (1)40.0 (2)66.7 (2)
Anti-CCP(% (n))0000
RF(% (n))30.8 (4)11.1 (1)00
ANA by IFI(% (n))011.1 (1)00

Conclusion:

In our cohort of patients with JIA, anti-MCV was highly specific when JIA patients were compared to a small group of controls, and the sensitivity of anti-MCV was superior to anti-CCP, since none of these patients presented anti-CCP antibodies. Further studies with larger sample sizes and including patients with others inflammatory diseases could help to better identify the clinical performance of anti-MCV in JIA.

To cite this abstract, please use the following information:
Lora, Priscila, Machado, Sandra, Xavier, Ricardo M.; Antibody against Mutated Citrullinated Vimentin (anti-MCV) as a Serological Marker for Juvenile Idiopathic Arthritis [abstract]. Arthritis Rheum 2009;60 Suppl 10 :251
DOI: 10.1002/art.25334

Abstract Supplement

Meeting Menu

2009 ACR/ARHP